Bioprinting has advanced rapidly over recent years through engineering step-changes in the use of 3D printing devices. With these developments, living cells can now be positioned layer-by-layer to produce functional tissue structures. Key attributes of this emerging technology are that it is scalable and highly customisable, which facilitates the manufacturing of a large variety of tissues in an automated and repeatable way. These capabilities equip developers with tools to advance 3D-tissues for broad applications, from in vitro drug testing models, to therapeutic tissue implants to whole organ transplants.
The bioprinting field is gaining traction at the commercial and technological level, but three key development hurdles are holding back bioprinting players attempting to evolve basic-demonstrative technologies through higher levels of proof and technical readiness.
Roundtable: Transitioning Medical Affairs to strategically co-lead clinical development and commercialization efforts
In May 2023, CRA’s Life Sciences Practice held a roundtable discussion with Medical Affairs leaders in Lisbon on best practices in transitioning from a...